secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2023-01-04T23:59:59+00:00
Accession:  0001193125-23-001193
Event type: leadership
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEO transition and positive FTX-6058 Phase 1b data; cash runway into late 2024
------------------------------------------------------------------------------

- CEO Bryan Stuart departs; Robert Gould, former CEO/board member, appointed interim CEO effective Jan 3, 2023.
- FTX-6058 granted FDA Fast Track for SCD; Phase 1b shows HbF increases up to 9.5% at 6 mg, generally well tolerated.
- Plan to complete enrollment in Phase 3 REACH trial of losmapimod in FSHD during 2H 2023.
- Cash runway expected to fund operations into late 2024; next FTX-6058 data update expected in Q4 2023.
- Phase 1b enrollment ongoing in 12 mg cohort; dose-dependent HbF increase observed across adherent patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312523001193/0001193125-23-001193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312523001193/d445531d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-001193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer